The Protein-Protein Interface Evolution Acts in a Similar Way to Antibody Affinity Maturation

Por Li, Bohua, Zhao, Lei, Wang, Chong, Guo, Huaizu, Wu, Lan, Zhang, Xunming, Qian, Weizhu, Wang, Hao, Guo, Yajun
Publicado em 2010

Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry

Por Zhu, Lei, Guo, Qingcheng, Guo, Huaizu, Liu, Tao, Zheng, Yingxin, Gu, Peiming, Chen, Xi, Wang, Hao, Hou, Sheng, Guo, Yajun
Publicado no MAbs (2014)

Identification of a Novel Functional Domain of Ricin Responsible for Its Potent Toxicity

Por Dai, Jianxing, Zhao, Lei, Yang, Haiou, Guo, Huaizu, Fan, Kexing, Wang, Huaqing, Qian, Weizhu, Zhang, Dapeng, Li, Bohua, Wang, Hao, Guo, Yajun
Publicado em 2011

Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab

Por Liang, Shuaiyi, Dai, Jianxin, Hou, Sheng, Su, Lishu, Zhang, Dapeng, Guo, Huaizu, Hu, Shi, Wang, Hao, Rao, Zihe, Guo, Yajun, Lou, Zhiyong
Publicado em 2013

Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy

Por Yang, Yun, Guo, Qingcheng, Chen, Xi, Zhang, Junjie, Guo, Huaizu, Qian, Weizhu, Hou, Sheng, Dai, Jianxin, Li, Bohua, Guo, Yajun, Wang, Hao
Publicado no MAbs (2016)

Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia

Por Jia, Gaozhen, Dong, Zhenyang, Sun, Chenxia, Wen, Fuping, Wang, Haifeng, Guo, Huaizu, Gao, Xu, Xu, Chuanliang, Xu, Chuanliang, Yang, Chenghua, Sun, Yinghao
Publicado no Oncotarget (2017)

Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View

Por Hu, Shi, Liang, Shuaiyi, Guo, Huaizu, Zhang, Dapeng, Li, Hui, Wang, Xiaoze, Yang, Weili, Qian, Weizhu, Hou, Sheng, Wang, Hao, Guo, Yajun, Lou, Zhiyong
Publicado em 2013

Comparison of the inhibition mechanisms of Adalimumab and Infliximab in treating tumor necrosis factor α-associated diseases from a molecular view.

Por Hu, Shi, Liang, Shuaiyi, Guo, Huaizu, Zhang, Dapeng, Li, Hui, Wang, Xiaoze, Yang, Weili, Qian, Weizhu, Hou, Sheng, Wang, Hao, Guo, Yajun, Lou, Zhiyong
Publicado em 2014

Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses

Por Liu, Boning, Guo, Huaizu, Xu, Jin, Qin, Ting, Guo, Qingcheng, Gu, Nana, Zhang, Dapeng, Qian, Weizhu, Dai, Jianxin, Hou, Sheng, Wang, Hao, Guo, Yajun
Publicado no MAbs (2017)

Molecular architecture of the ErbB2 extracellular domain homodimer

Por Hu, Shi, Sun, Yuna, Meng, Yanchun, Wang, Xiaoze, Yang, Weili, Fu, Wenyan, Guo, Huaizu, Qian, Weizhu, Hou, Sheng, Li, Bohua, Rao, Zihe, Lou, Zhiyong, Guo, Yajun
Publicado no Oncotarget (2015)

Characterization of alanine to valine sequence variants in the Fc region of nivolumab biosimilar produced in Chinese hamster ovary cells

Por Li, Yantao, Fu, Tuo, Liu, Tao, Guo, Huaizu, Guo, Qingcheng, Xu, Jin, Zhang, Dapeng, Qian, Weizhu, Dai, Jianxin, Li, Bohua, Guo, Yajun, Hou, Sheng, Wang, Hao
Publicado no MAbs (2016)

Acid-induced aggregation propensity of nivolumab is dependent on the Fc

Por Liu, Boning, Guo, Huaizu, Xu, Jin, Qin, Ting, Xu, Lu, Zhang, Junjie, Guo, Qingcheng, Zhang, Dapeng, Qian, Weizhu, Li, Bohua, Dai, Jianxin, Hou, Sheng, Guo, Yajun, Wang, Hao
Publicado no MAbs (2016)

Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency

Por Yang, Yun, Guo, Qingcheng, Xia, Mao, Li, Yantao, Peng, Xiaoyun, Liu, Tao, Tong, Xin, Xu, Jin, Guo, Huaizu, Qian, Weizhu, Hou, Sheng, Dai, Jianxin, Wang, Hao, Liu, Rong, Guo, Yajun
Publicado no MAbs (2015)